The efficacy and safety of oral desmopressin in children with primary nocturnal enuresis.

Schulman SL, Stokes A, Salzman PM

The Journal of urology1 Dec 2001Cited by 29 (Europe PMC)

PMID11696804DOI10.1016/s0022-5347(05)65608-xPepBankPUB-11696804

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

01HumanRandomized controlled trialEfficacy outcome
In children with enuresis, desmopressin showed a significant linear dose response from 0.2 to 0.6 mg (p <=0.05).
In plain wordsIn children with enuresis, desmopressin showed a significant linear dose response from 0.2 to 0.6 mg.
Peptide
Desmopressin
Outcome
Not applicableDose response
Study
n = 193
Outcome group
Enuresis · Kidney and urinary
Studied dose
0.2-0.6 mg · oral · 2 weeksAs given in this study (human).
Source sentences
Summary
There was a statistically significant linear response to oral desmopressin at doses from 0.2 to 0.6 mg. during the dose ranging phase (p < or =0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
We evaluated the safety and efficacy of oral desmopressin in a double-blind, placebo controlled, parallel group, randomized, multicenter trial of 193 children 6 to 16 years old with documented primary nocturnal enuresis.
Summary · context
The study was conducted in 2 phases: 1) a 2-week dose ranging phase in which children received desmopressin (0.2, 0.4 or 0.6 mg.) or placebo at bedtime and 2) an 8-week dose titration phase that followed a 2-week placebo washout.
Report a problemFND-1169680401
02HumanRandomized controlled trialEfficacy outcome
In children with enuresis, wet nights decreased 27% with desmopressin 0.2 mg versus 10% with placebo (p <=0.05).
In plain wordsIn children with enuresis, wet nights decreased 27% with desmopressin 0.2 mg versus 10% with placebo.
Peptide
Desmopressin
Outcome
DecreaseWet nights
Study
n: not reported in source
Comparator
Placebo
Outcome group
Enuresis · Kidney and urinary
Studied dose
0.2 mg · oral · 2 weeksAs given in this study (human).
Measurements
Decrease in wet nights
27%
desmopressin 0.2 mg, after 2 weeks
Decrease in wet nights
10%
placebo, after 2 weeks
Source sentences
Summary
The decrease in wet nights after 2 weeks of treatment with desmopressin was 27%, 30% and 40% at 0.2, 0.4 and 0.6 mg. doses, respectively, compared to 10% with placebo.
3 context sentences(design, population, supporting numbers)
Summary · context
All doses were statistically significantly different from placebo (p < or =0.05).
Summary · context
We evaluated the safety and efficacy of oral desmopressin in a double-blind, placebo controlled, parallel group, randomized, multicenter trial of 193 children 6 to 16 years old with documented primary nocturnal enuresis.
Summary · context
The study was conducted in 2 phases: 1) a 2-week dose ranging phase in which children received desmopressin (0.2, 0.4 or 0.6 mg.) or placebo at bedtime and 2) an 8-week dose titration phase that followed a 2-week placebo washout.
Report a problemFND-1169680402
03HumanRandomized controlled trialEfficacy outcome
In children with enuresis, wet nights decreased 30% with desmopressin 0.4 mg versus 10% with placebo (p <=0.05).
In plain wordsIn children with enuresis, wet nights decreased 30% with desmopressin 0.4 mg versus 10% with placebo.
Peptide
Desmopressin
Outcome
DecreaseWet nights
Study
n: not reported in source
Comparator
Placebo
Outcome group
Enuresis · Kidney and urinary
Studied dose
0.4 mg · oral · 2 weeksAs given in this study (human).
Measurements
Decrease in wet nights
30%
desmopressin 0.4 mg, after 2 weeks
Decrease in wet nights
10%
placebo, after 2 weeks
Source sentences
Summary
The decrease in wet nights after 2 weeks of treatment with desmopressin was 27%, 30% and 40% at 0.2, 0.4 and 0.6 mg. doses, respectively, compared to 10% with placebo.
3 context sentences(design, population, supporting numbers)
Summary · context
All doses were statistically significantly different from placebo (p < or =0.05).
Summary · context
We evaluated the safety and efficacy of oral desmopressin in a double-blind, placebo controlled, parallel group, randomized, multicenter trial of 193 children 6 to 16 years old with documented primary nocturnal enuresis.
Summary · context
The study was conducted in 2 phases: 1) a 2-week dose ranging phase in which children received desmopressin (0.2, 0.4 or 0.6 mg.) or placebo at bedtime and 2) an 8-week dose titration phase that followed a 2-week placebo washout.
Report a problemFND-1169680403
04HumanRandomized controlled trialEfficacy outcome
In children with enuresis, wet nights decreased 40% with desmopressin 0.6 mg versus 10% with placebo (p <=0.05).
In plain wordsIn children with enuresis, wet nights decreased 40% with desmopressin 0.6 mg versus 10% with placebo.
Peptide
Desmopressin
Outcome
DecreaseWet nights
Study
n: not reported in source
Comparator
Placebo
Outcome group
Enuresis · Kidney and urinary
Studied dose
0.6 mg · oral · 2 weeksAs given in this study (human).
Measurements
Decrease in wet nights
40%
desmopressin 0.6 mg, after 2 weeks
Decrease in wet nights
10%
placebo, after 2 weeks
Source sentences
Summary
The decrease in wet nights after 2 weeks of treatment with desmopressin was 27%, 30% and 40% at 0.2, 0.4 and 0.6 mg. doses, respectively, compared to 10% with placebo.
3 context sentences(design, population, supporting numbers)
Summary · context
All doses were statistically significantly different from placebo (p < or =0.05).
Summary · context
We evaluated the safety and efficacy of oral desmopressin in a double-blind, placebo controlled, parallel group, randomized, multicenter trial of 193 children 6 to 16 years old with documented primary nocturnal enuresis.
Summary · context
The study was conducted in 2 phases: 1) a 2-week dose ranging phase in which children received desmopressin (0.2, 0.4 or 0.6 mg.) or placebo at bedtime and 2) an 8-week dose titration phase that followed a 2-week placebo washout.
Report a problemFND-1169680404
05HumanRandomized controlled trialEfficacy outcome
During titration in children with enuresis, 87% receiving desmopressin and all receiving placebo took the maximum dose of 3 tablets nightly.
In plain wordsDuring titration in children with enuresis, 87% receiving desmopressin and all receiving placebo took the maximum nightly dose.
Peptide
Desmopressin
Outcome
Not applicableMaximum dose requirement
Study
n: not reported in source
Comparator
Placebo
Outcome group
Enuresis · Kidney and urinary
Studied dose
Dose not stated · oral · 8-week titration phaseAs given in this study (human).
Measurements
Patients receiving maximum dose of 3 tablets nightly
87%
desmopressin-treated patients, dose titration phase
Source sentences
Summary
During the dose titration phase all placebo treated and 87% of desmopressin treated patients were receiving the maximum dose of 3 tablets nightly because they had not been completely dry in the previous 2 weeks.
2 context sentences(design, population, supporting numbers)
Summary · context
We evaluated the safety and efficacy of oral desmopressin in a double-blind, placebo controlled, parallel group, randomized, multicenter trial of 193 children 6 to 16 years old with documented primary nocturnal enuresis.
Summary · context
The study was conducted in 2 phases: 1) a 2-week dose ranging phase in which children received desmopressin (0.2, 0.4 or 0.6 mg.) or placebo at bedtime and 2) an 8-week dose titration phase that followed a 2-week placebo washout.
Report a problemFND-1169680405
06HumanNon-randomized trialEfficacy outcome
In children with enuresis, 44% receiving desmopressin achieved at least a 50% reduction in wet nights at doses of 0.2 and 0.4 mg.
In plain wordsIn children with enuresis, 44% receiving lower desmopressin doses achieved at least a 50% reduction in wet nights.
Peptide
Desmopressin
Outcome
DecreaseAt least half reduction in wet nights
Study
n: not reported in source
Outcome group
Enuresis · Kidney and urinary
Studied dose
0.2 and 0.4 mg · oralAs given in this study (human).
Measurements
Patients with at least 50% reduction in wet nights
44%
desmopressin-treated patients at 0.2 and 0.4 mg
Source sentences
Summary
Nevertheless, 44% of desmopressin treated patients had achieved at least a 50% reduction from baseline in the number of wet nights per 2 weeks at the lower doses of 0.2 and 0.4 mg.
2 context sentences(design, population, supporting numbers)
Summary · context
We evaluated the safety and efficacy of oral desmopressin in a double-blind, placebo controlled, parallel group, randomized, multicenter trial of 193 children 6 to 16 years old with documented primary nocturnal enuresis.
Summary · context
The study was conducted in 2 phases: 1) a 2-week dose ranging phase in which children received desmopressin (0.2, 0.4 or 0.6 mg.) or placebo at bedtime and 2) an 8-week dose titration phase that followed a 2-week placebo washout.
Report a problemFND-1169680406

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
28 Oct 2026, 02:03 UTC
Study results updated
Version 1
27 Oct 2026, 16:35 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.